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OBJECTIVE: The aim of this study was to evaluate the role of angiotensin I, II and 1–7 on left ventricular hypertrophy
of Wistar and spontaneously hypertensive rats submitted to sinoaortic denervation.
METHODS: Ten weeks after sinoaortic denervation, hemodynamic and morphofunctional parameters were
analyzed, and the left ventricle was dissected for biochemical analyses.
RESULTS: Hypertensive groups (controls and denervated) showed an increase on mean blood pressure compared
with normotensive ones (controls and denervated). Blood pressure variability was higher in denervated groups than
in their respective controls. Left ventricular mass and collagen content were increased in the normotensive
denervated and in both spontaneously hypertensive groups compared with Wistar controls. Both hypertensive
groups presented a higher concentration of angiotensin II than Wistar controls, whereas angiotensin 1–7
concentration was decreased in the hypertensive denervated group in relation to the Wistar groups. There was no
difference in angiotensin I concentration among groups.
CONCLUSION: Our results suggest that not only blood pressure variability and reduced baroreflex sensitivity but also
elevated levels of angiotensin II and a reduced concentration of angiotensin 1–7 may contribute to the development
of left ventricular hypertrophy. These data indicate that baroreflex dysfunction associated with changes in the renin
angiotensin system may be predictive factors of left ventricular hypertrophy and cardiac failure.
KEYWORDS: Angiotensins; Left ventricular hypertrophy; SAD; Spontaneously hypertensive rats; Collagen.
Piratello AC, Moraes-Silva IC, Paulini J, Souza PR, Sirvente R, Salemi V, Flues K, Moreira ED, Mostarda C, Cunha T, Casarini DE, Irigoyen MC. Renin
angiotensin system and cardiac hypertrophy after sinoaortic denervation in rats. Clinics. 2010;65(12):1345-1350.
Received for publication on July 20, 2010; First review completed on August 9, 2010; Accepted for publication on September 12, 2010
E-mail: hipirigoyen@incor.usp.br
Tel.: 55 11 3069-5006
INTRODUCTION
Arterial baroreflex is the main mechanism for the
regulation of the cardiovascular system, and sinoaortic
denervation (SAD) is a widely used tool to study its
function.1 It is well established that chronic SAD increases
blood pressure variability (BPV) without increasing mean
blood pressure.2 Previous studies have demonstrated that
BPV,3 baroreflex sensitivity,4 and the renin angiotensin
system (RAS)5 were independent determinants in hyperten-
sive end-organ damage in rats.
In addition to the classic circulating RAS, there is growing
evidence supporting the existence of a local functioning
cardiac RAS.6 All components of the RAS (renin, angioten-
sinogen, angiotensin-converting enzyme (ACE), and angio-
tensin II receptors) are identified in the heart at the mRNA
and protein levels,7 and this system is activated in
experimental left ventricular hypertrophy (LVH) induced
by hemodynamic overload.8
The hypertension-induced LVH initially serves as an
adaptive ventricular response to pressure overload; never-
theless, it is a major independent risk factor associated with
increased cardiovascular morbidity and mortality.9
The aim of this study was to evaluate ventricular
hypertrophy parameters induced by baroreflex impairment
and the contribution of the local cardiac angiotensins (Ang)
I, II and 1–7 in this process in normotensive (Wistar) and
hypertensive (SHR) rats.
MATERIALS AND METHODS
Animals
Experiments were performed on male Wistar and SHR
rats aged 16 weeks,10 housed in cages with free access to
water and food, and maintained in a room with a constant
temperature (23 C˚) on a 12-hour light–dark cycle. All
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surgical procedures and protocols used were in accordance
with the Guidelines for Ethical Care of the Experimental
Animals and were approved by the Institutional Animals
Care and Use Committee (CEP 1016/08). Rats were
randomized into four groups: Wistar control (WC), N = 9,
Wistar denervated (WD), N = 7, SHR control (SHRC) N = 8,
SHR denervated (SHRD) N = 8.
Sinoaortic denervation
SAD was performed under anesthesia with ketamine,
80 mg/kg (Parke-Davis, Brazil) and Xylazine, 12 mg/kg
(Bayer, Brazil). A 3-cm midline incision was made, and
sternocleidomastoid muscles were reflected laterally, expos-
ing the neurovascular sheath. The common carotid arteries
and the vagal trunk were isolated, and the aortic depressor
fibers either traveling with the sympathetic nerve or as an
isolated aortic nerve were cut. The communicating branch
of the aortic fibers was also resected. The third contingent of
aortic baroreceptor fibers traveling with the inferior
laryngeal nerve was interrupted by resection of the superior
laryngeal nerve after the carotid bifurcation was exposed
extensively for carotid stripping. To complete the proce-
dure, the sinus nerve, all carotid branches and the carotid
body were resected.11
The mortality rate was 35% higher in the animals
submitted to SAD than in their respective controls.
Hemodynamic measurements
Ten weeks after SAD, animals were anesthetized with
ketamine, 80 mg/kg (Parke-Davis, Brazil) and xylazine,
12 mg/Kg (Bayer, Brazil), and femoral artery and vein
catheters were inserted for direct measurements of blood
pressure (BP), heart rate (HR) and drug administration.
Twenty-four hours after catheterization, the arterial
catheter was connected to a transducer (Blood Pressure
XDCR, Kent Scientific, Litchfield, CT), and BP signals were
recorded in conscious, freely moving rats, over a 30-min
period by a microcomputer equipped with an analog-to-
digital converter board (Windaq, 2000 Hz sampling fre-
quency, Dataq Instruments, Inc, Akron, OH). The recorded
data were analyzed on a beat-to-beat basis to quantify
changes in mean BP and HR. Both BP and HR variability
were evaluated using the mean of the standard deviation.
Baroreflex sensitivity evaluation
Increasing doses of phenylephrine (0.25–32.0 mg/kg) and
sodium nitroprusside (0.05–1.6 mg/kg) were given as sequen-
tial bolus injections (0.1 mL) to produce pressure responses
ranging from 5 to 30 mmHg. A 3- to 5-min interval between
doses was necessary for BP to return to baseline. Peak
increases or decreases in mean BP after vasoactive drugs
injection and the corresponding peak reflex changes in HR
were recorded for each dose of the drug. Baroreflex sensitivity
was evaluated by a mean index that associated changes in HR
to the changes in mean BP, thus allowing for a separate
analysis of gain for reflex bradycardia and reflex tachycar-
dia.12 The mean index was expressed as bpm/mmHg.
Left ventricular hypertrophy evaluation
LVH was evaluated in animals at 16 weeks of age by
ventricular hypertrophy index (calculated by LV/body mass
index (mg/g)), echocardiography and LV collagen volume
fraction.
Echocardiography
Echocardiographic variables were obtained according to
the recommendations of the American Society of
Echocardiography. Transthoracic echocardiography was
performed in all the groups, by double-blind observers
with the use of a SEQUOIA 512 (ACUSON Corporation,
Mountain View, CA), which offers a 10–13 MHz multi-
frequency linear transducer. Images were obtained with the
transducer placed on each animal’s shaved chest (lateral
recumbence). To obtain a more distinctive image display, a
transmission gel was used between the transducer and the
animal’s chest (General Imaging Gel, ATL, Reedsville, PA).
Animals were scanned from below, at a 2-cm depth with
focus optimized at 1 cm. All measurements were based on
the average of three consecutive cardiac cycles. Rats were
anesthetized with a combination of ketamine, 80 mg/kg
(Parke-Davis) and xylazine, 12 mg/kg (Bayer) i.p. Wall
thickness and left ventricular (LV) dimensions were
obtained from a short-axis view at the level of the papillary
muscles. LV mass was calculated by using the following
formula, assuming a spherical LV geometry and validated
in rats: LV mass = 10476 [(LVd + PWd + IVSd)3 2 LVd3],
where 1047 is the specific gravity of muscle, LVd is LV end-
diastolic diameter, PWd is end-diastolic posterior wall
thickness and IVSd is end-diastolic interventricular septum
thickness. In addition, another morphological index was
evaluated, the relative wall thickness (RWT), which is
expressed by 2 6 PWD/LVd. It represents the relation
between the LV cavity in diastole and the LV posterior wall.
LV fractional shortening was calculated as (LVd 2 LVs)/
LVd 6 100, where LVs is LV end-systolic diameter. Two-
dimensional guided pulsed-wave Doppler recordings of LV
inflow were obtained from the apical four-chamber view.
Maximal early diastolic peak velocity (E) and late peak
velocity (A) were derived from mitral inflow. The LV
outflow tract velocity was measured just below the aortic
valve, from an apical five-chamber view. The velocity of
circumferential fiber shortening (VCF) was measured
following the formula (LVd 2 LVs)/(LVd 6 ET), where
ET is the ejection time. The sample volume was then placed
between the mitral valve and LV outflow tract so that the
aortic valve closure line and the onset of mitral flow could
be clearly identified. The isovolumic relaxation time (IVRT)
was measured from aortic valve closure to the onset of
mitral flow. Global cardiac function was evaluated by using
the myocardial performance index (MPI), which is the ratio
of total time spent in isovolumic activity (isovolumic
contraction time and isovolumic relaxation time) to the
ET. These Doppler time intervals were measured from the
mitral inflow and LV outflow time intervals. Interval ‘‘a’’,
from the cessation to onset of mitral inflow is equal to the
sum of the isovolumic contraction time, ET and isovolumic
relaxation time. Ejection time ‘‘b’’ is derived from the
duration of the LV outflow Doppler velocity profile. The
MPI was calculated with the formula (a 2 b)/b.
Collagen volume fraction evaluation
At the end of the experimental protocol, a transverse
incision below the diaphragm and bilateral thoracotomy
incisions were performed in the sodium pentobarbital
(40 mg/kg i.p.) anesthetized rats, in order to expose the
heart. A needle (406 12) was carefully introduced into the
LV apex. The animal’s heart was arrested in diastole by
perfusion with a NaCl 0.9% plus 14 mM KCl solution
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(pressure equal to a 13 cm water column), followed by 4%
tamponed formalin for tissue fixation. Hearts were excised,
trimmed, weighed and immersed in paraformol 4% in PBS
for 24 h. Thereafter, the heart was transected perpendicular
to the long axis and processed and embedded in paraffinso that
histological sections could be performed. Histomorphometric
analyses were performed blinded regarding the identity of the
experimental groups. LV sections of 3 mm were stained with
picrosirius red for collagen quantification.13 Computerized
image acquisition (Nikon Optiphot) and analysis were used to
access collagen volume fraction in LV of all studied animals
using the digital image analyzer program Image Pro Plus 6.0
(Media Cybernetics, USA).14
Quantification of angiotensins I, II and 1–7 by high-
performance liquid chromatography
Tissue was homogenized as described by Oliveira et al.15
in 100 mmol/L phosphate buffer (PB), pH 7.2, containing
340 mmol/L sucrose, 300 mmol/L NaCl (1 g tissue: 10 mL
buffer) and inhibitor PMSF(100 mmol/L). The homogenates
were centrifuged at 3.000 rpm, at 40 C˚ for 10 min and the
supernatant was frozen at 270 C˚ until experimental use.
Angiotensins I, II, and 1–7 were quantified in tissue
extracts using reverse-phase high-performance liquid chro-
matography coupled with ultraviolet (214 nm) detection
(HPLC-UV). Peptide separation was accomplished using a
4.6 6 250 mm, 7-mm Aquapore OD 300 column (Applied
Biosciences, Foster City, CA), equilibrated with 0.1%
phosphoric acid in 5% acetonitrile. The peptides were
initially separated by isocratic elution for 5 min, followed
by a linear gradient from 5% to 35% acetonitrile in 0.1%
phosphoric acid for 20 min at a flow rate of 1.5 mL/min. The
left ventriclewas pre-homogenized in 8 mL of 0.1 M sodium
phosphate buffer containing 0.34 M sucrose and 0.3 M NaCl
(pH 7.2). Angiotensin III (320 ng) was added to each sample
as an internal standard. Extraction of angiotensins I, II and
1–7 was achieved using Sep-Pak-C18 column chromatogra-
phy (Millipore, Milford, MA). The column was activated
with the following steps: 5 mL of methanol, 5 mL of
tetrahydrofuran, 5 mL of hexane, 5 mL of methanol, and
10 mL of H2O (MilliQ water). The samples were then loaded
onto the column and eluted by the following steps: 10 mL of
H2O, 5 mL of 4% acetic acid, and 5 mL of ethanol/acetic
acid/H2O (9046, v/v). The peptides were eluted in the last
phase and were evaporated to dryness in a SpeedVac SC110
sample concentrator (Savant Instruments, Holbrook, NY).
Sample extracts were reconstituted with 500 mL of 0.1%
phosphoric acid in 5% acetonitrile, after which they were
filtered and injected onto the analytical column of the HPLC
system. Retention time was used to identify peaks of
interest, previously determined by the elution of peptide
standards. Calculations were based on peak area, and
angiotensins I, II and 1–7 concentrations were expressed
as nmol/g of tissue.
RESULTS
Data are presented as mean¡ SEM. Two-way analysis of
variance (ANOVA) followed by the Student–Newman–
Keuls post hoc test was used. Statistical significance was
considered when p , 0.05.
Hypertensive groups (SHRC and SHRD) showed higher
values in mean blood pressure than the normotensive
groups (WC and WD) (155 ¡ 2.2; 162 ¡ 7.3 vs 100 ¡ 1.8;
100 ¡ 2.8 mmHg, respectively).
Baroreflex sensitivity was evaluated to confirm the
denervation. Tachycardia and bradycardia indexes in WD
group were 0.44 ¡ 0.08 and 20.63 ¡ 0.05 bpm/mmHg,
respectively; in the SHRD group, the tachycardia index was
0.23 ¡ 0.03 bpm/mmHg and bradycardia index was 20.67
¡ 0.09 bpm/mmHg. These results confirm the baroreflex
dysfunction caused by chronic SAD.
The BPV (expressed by standard deviation) was increased
in the groups submitted to SAD compared with their
respective controls, and the SHRD group presented
increased values of BPV compared with the other groups
(Fig. 1).
Animals of the WD, SHRC and SHRD groups presented
higher ventricular hypertrophy index than WC, and SAD
associated with hypertension induced a higher increase in
left ventricle mass in the SHRD group (Fig. 2).
The size of left ventricle cavity in diastole (LVDIA) was
increased in the animals of the hypertensive groups (SHRC
and SHRD). The interventricular septum (IVS) and left
ventricle posterior wall (LVPW) were increased in WD and
SHR groups. The relative wall thickness (RWT) and left
ventricle mass (LVM) were increased in the WD, SHRC and
SHRD groups, and the SHR groups presented increased
values of LVM compared with WD group.
Isovolumic relation time (IVRT) was increased in the WD,
SHRC, SHRD groups. The E/A ratio was lower in the WD
group than the WC group; and animals of the SHR groups
presented increased values compared with the WD group.
Only the animals of the WD group presented increased
values of ejection fraction (EF) and velocity of circumfer-
ential shortening (VCF) compared with the WC group
(Table 1).
Left ventricular fibrosis, accessed by collagen volume
fraction evaluation (Fig. 3A,B), showed that hypertensive
rats (SHR and SHRD) presented increased percentage of
Figure 1 - Blood pressure variability (BPV) of the Wistar control (WC), Wistar denervated (WD), SHR control (SHRC), SHR denervated
(SHRD) groups *p,0.05 vs WC; #p,0.05 vs WD; +p,0.05 vs SHRC.
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collagen compared with normotensive groups.
Interestingly, denervated rats (WD and SHRD) had sharply
increased collagen content compared with baroreflex intact
rats.
Fig. 4 shows the concentration of the Ang I, Ang II and
Ang 1–7 in the left ventricle of different groups. Ang II
concentration was increased in the SHR groups compared
with the WC group, whereas the Ang 1–7 concentration was
decreased in the SHRD group compared with the Wistar
groups.
DISCUSSION
Chronic SAD (10 weeks) did not increase the BP and HR
of normotensive and hypertensive groups. However, BPV
was increased in the SHRD group compared with all
groups. Additionally, SAD also increased the BPV in
Wistar groups, as the variability became the same as the
SHR animals without denervation.
The most consistent cardiovascular alteration produced by
acute or chronic SAD is the huge increase in BPV. Previous
studies have described similar high variability in dogs,16 cats17
and rats.18 Usually, the BPV in SAD animals is characterized
by an increase in the BP standard mean, obtained through the
moment-to-moment records of BP signals.18
The increased BPV may be due to the absence of straight
beat-to-beat synchronization between BP and sympathetic
nerve activity normally provided by baroreceptors.2
The ventricular hypertrophy index was increased in
SHRD compared with SHRC, and in the SHRC compared
with WC, which suggests that hypertension may play a role
in the development of the LVH. This also seems to indicate
that hypertension associated with the BPV and baroreflex
sensitivity damage results in a higher LVH.
A similar behavior was observed for the collagen volume
fraction, an important marker of pathological LVH. The
collagen network may help to maintain cardiac muscle
structural organization, may facilitate tensile strength trans-
mission from cardiomyocytes to LV, and may contribute
Figure 2 - Hypertrophy ventricular index (LVM/body weight) of
the Wistar control (WC), Wistar denervated (WD), SHR control
(SHRC), SHR denervated (SHRD) groups *p,0.05 vs WC; #p,0.05
vs WD; +p,0.05 vs SHRC.
Table 1 - Echocardiography parameters of the Wistar control (WC), Wistar denervated (WD), SHR control (SHRC), SHR
denervated (SHRD) groups.
WC WD SHRC SHRD
LVDIACORR (cm/g) 1.85 ¡ 0.04 1.72 ¡ 0.06 2.25 ¡ 0.08*# 2.61 ¡ 0.12*#
IVS (cm/g) 0.27 ¡0.007 0.36 ¡ 0.01* 0.61 ¡ 0.01*# 0.56 ¡ 0.01*#+
LVPW (cm/g) 0.27 ¡ 0.008 0.37 ¡ 0.01* 0.61 ¡ 0.01*# 0.55 ¡ 0.01*#+
RWT (cm) 0.29 ¡ 0.008 0.43 ¡ 0.03* 0.55 ¡ 0.02*# 0.43 ¡ 0.02*+
LVM (mg/g) 2.58 ¡ 0.06 2.88 ¡ 0.06* 4.02 ¡ 0.1*# 4.11 ¡ 0.13*#
IVRT (ms) 23 ¡ 0.56 26 ¡ 1.69* 27 ¡ 0.70* 29 ¡ 0.73*
E/A ratio 1.92 ¡ 0.09 1.21 ¡ 0.66* 1.87 ¡ 0.08# 1.97 ¡ 0.21#
EF (%) 72 ¡ 1 80 ¡ 2* 77 ¡ 2 77 ¡ 3
VCF (circ/s*103) 0.004 ¡ 0,0002 0.0059 ¡ 0,0004* 0.0053 ¡ 0,0003 0.0051 ¡ 0,0003
Mean ¡ SEM *p,0,05 vs WC, #p ,0,05 vs WD,+ p,0,05 vs SHRC.
Figure 3 - A, Collagen volume fraction in the left ventricle of
Wistar control (WC), Wistar denervated (WD), SHR control
(SHRC), and SHR denervated (SHRD) groups. B, Representative
photomicrography of collagen fibers in the left ventricle of WC,
WD, SHRC, SHRD. *p,0.05 vs WC, #p,0.05 vs WD, + p,0.05 vs
SHRC.
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towards myocardial relaxation. Equally important, the
collagen network is responsible for myocardial passive
stiffness and for ventricular volume.13 Despite these
beneficial aspects of the collagen network, pressure over-
load to the heart may cause excessive accumulation of
collagen fibers among cardiac cells due to mechanisms yet
to be fully understood. This process, known as fibrosis,
considerably increases cardiac tissue stiffness, impairing
cardiac function.19 Reparative and reactive fibrosis may
occur in different situations. In hypertension, the reactive
fibrosis to increased pressure overload seems to be linked to
myocyte apoptosis.20 In addition, since increased BPV is
associated with enhanced end-organ damage4, the amount
of collagen in the heart of denervated rats is consequently
augmented. In this study, we showed that baroreflex
impairment may mediate these stimuli regardless of
pressure overload, as denervated rats presented increased
collagen volume fraction, and when SAD was associated
with hypertension this increase became considerably more
evident.
Both hypertension and high BPV are involved in
cardiovascular damage. A study carried out by Miao et
al.21 showed that in the SHR (hypertension accompanied by
an elevated BPV) the LVH is more severe than in animals
with chronic SAD (only elevated BPV, without hyperten-
sion), corroborating our findings of a positive correlation
between left ventricle mass and BPV (r = 0.56). This
correlation has also been described by Van Vliet et al.22 in
animals submitted to carotid denervation, SAD and mod-
ified SAD (preservation of the carotid chemoreceptors).
Our results for left ventricle angiotensins show that SHR
groups presented increased Ang II levels compared with
WC. Classically, RAS is a systematic regulator in various
biological activities. Ang II is the key effector of RAS and a
vasoconstrictor acting in the cardiovascular system.23 Li et
al.24 have shown that the gene expressions of all compo-
nents of RAS were elevated in the heart and aorta of the
SHR compared with Wistar Kyoto rats. This significant
increase lends supports to the hypothesis that activation of
local tissue RAS may contribute to cardiac hypertrophy and
arterial remodeling.
RAS plays a central role in the development of hyperten-
sion and the progression of end-organ damage.5 Our results
showed a positive correlation between the cardiac hyper-
trophy index and Ang II levels (r = 0.41), thus corroborating
other data in that this peptide is closely related to the
development of the cardiac hypertrophy.25
Li et al.24 have suggested that the LVH in SHR was
associated with ACE and ACE2 gene expression cardiac
RAS, while aortic hypertrophy was associated with angio-
tensinogen and ACE2 gene expression of aortic RAS. This
seems to support the postulation that, since there is no
correlation between the plasma Ang II concentration and
organ damage parameters, it is indeed the tissue RAS which
may exert a detrimental effect on cardiovascular function26
rather than the circulating RAS. Miao et al.27 have shown
that plasma and tissue Ang II concentrations remain
unaltered after chronic SAD (2, 10 and 16 weeks).
Accordingly, our study could not find any significant
differences between animals submitted to SAD compared
with each control group, although a qualitative tendency
may be observed in the WD group compared with the
control.
On the other hand, Shan et al.28 have observed an increase
in the Ang II levels in the cardiac and kidney tissues of rats
submitted to chronic SAD, and these Ang II levels were
more elevated when these animals were submitted to
chronic stress, suggesting that elevated BPV and Ang II
liberation may be related to end-organ damage develop-
ment induced by baroreflex dysfunction.
In transgenic animals the overexpression of the angioten-
sinogen gene in the cardiac myocytes resulted in increased
cardiac Ang II concentration and right and left ventricular
hypertrophy, unaccompanied by either hypertension or
increased circulating levels of Ang II.29 These data strongly
suggest that Ang II may induce cardiac hypertrophy
regardless of its hemodynamic effects.
In our data, Ang I levels were not statistically different
among groups. This finding corroborates Campbell et al.30
when comparing SHR to normotensive control animals.
A reduced Ang 1–7 concentration in the SHRD group was
observed compared with normotensive groups. Campbell et
al.30 found similar results when comparing SHR (20 weeks)
with Donryu rats as a control group.
Previous studies have shown that Ang 1–7 partially
prevented the pressoric response elicited by Ang II in SAD
rats but not in sham-operated animals.31 It is well
established that Ang 1–7 can act as a physiological
antagonist of Ang II by means of the activation of
MASreceptors, which in turn blocks the vasoconstrictor
effect of Ang II.32
Different researchers have shown that opposite effects of
Ang II are enhanced in animal models of hypertension.33
Benter et al.34 have demonstrated that Ang 1–7 attenuates
Ang II vasoconstriction in SHR but not in normotensive
animals. Other studies (Ho¨cht et al.31) have also demon-
strated that Ang 1–7 blocked the pressor response to Ang II
in hypertensive SHR and aortic coarcted rats, but not in
normotensive control rats. The enhanced effect of Ang 1–7
in situations of Ang II overactivity may be related to an
increased sensitivity to Ang 1–7.
In our data, the qualitative and quantitative reduction of
the Ang 1–7 levels were accompanied by the significant
increase in the Ang II levels. This reduction of Ang 1–7 may
be related to the increase in its sensitivity in the attempt to
tone down the effects generated by Ang II overactivity.
CONCLUSIONS
Our results suggest that not only BP variability and reduced
baroreflex sensitivity may contribute to the development of
Figure 4 - Angiotensins I, II and 1–7 in left ventricle of Wistar
control (WC), Wistar denervated (WD), SHR control (SHRC), SHR
denervated (SHRD) groups. *p,0.05 vs WC, #p,0.05 vs WD.
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left ventricular hypertrophy as previously suggested; our
findings indicate that elevated levels of Ang II and reduced
concentration of Ang 1–7 may also play a role in this process.
These data indicate that baroreflex dysfunction associated
with changes of RAS may be predictive factors of LVH and
cardiac failure.
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